Latest Breaking News On - Kim phelan - Page 4 : comparemela.com

FDA approves CSL hemophilia gene therapy - BioProcess Insider

With a list price of $3.5 million, Hemgenix becomes the most expensive single-dose drug and the first gene therapy approved for hemophilia B.

FDA approves $3.5 million gene therapy for hemophilia

The Food and Drug Administration (FDA) approved a drug to treat adults with hemophilia B, a rare blood clotting disorder.

uniQure announces FDA approval of first gene therapy for adults with hemophilia B

U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B

/PRNewswire/ Global biotechnology leader CSL (ASX: CSL) today announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene.

U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B